SCHEMBL23975360

SCHEMBL23975360

O=C(CCOCCOCCNc1ccccc1)NCCCCCCCCNC(=O)C1CCCCCC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
PKM P14618 1/20 0.50
EPHX2 P34913 1/20 0.50
RAB9A P51151 1/20 0.50
NAMPT P43490 1/20 0.47
NAAA Q02083 1/20 0.44
KMT2A Q03164 2/20 0.44
DRD2 P14416 3/20 0.44
DRD3 P35462 3/20 0.44
HPGD P15428 1/20 0.43
ALDH1A1 P00352 2/20 0.42
EPHX1 P07099 1/20 0.42
ADRA1A P35348 1/20 0.41
MEN1 O00255 1/20 0.41
TERT O14746 1/20 0.41
LMNA P02545 1/20 0.40
ALOX12 P18054 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23975139 0.99 SMN1; SMN2 (0.48) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975358 0.82 NAMPT (0.54) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL21842318 0.81 L3MBTL1 (0.48) SMN1; SMN2KMT2AHPGDADRA1AMEN1
SCHEMBL23975359 0.80 NAAA (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL21842289 0.80 NAAA (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975140 0.80 NAAA (0.50) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975366 0.73 SMN1; SMN2 (0.85) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975365 0.73 SMN1; SMN2 (0.44) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL23975361 0.73 SMN1; SMN2 (0.44) SMN1; SMN2NPC1PKMEPHX2RAB9A
SCHEMBL21842360 0.73 SMN1; SMN2 (0.44) SMN1; SMN2NPC1PKMEPHX2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338825-A1 DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338825-A1 DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN HAVCR2, CUL4A, PSMC3 SMN1; SMN2 3617/4885NPC1 734/4885PKM 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.